Literature DB >> 22964447

Phenotypic heterogeneity in consanguineous patients with a common CLN8 mutation.

Muhammad Mahajnah1, Nathanel Zelnik.   

Abstract

The most heterogeneous subtype of neuronal ceroid lipofuscinosis comprises the late infantile variant, which, in addition to the classic CLN2, was reported in children with CLN5, CLN6, CLN7/MFSD8, and CLN8 genes. Patients with CLN8 mutations usually present as the late-infantile-onset neuronal ceroid lipofuscinosis phenotype and are mostly Turkish and Italian, but three patients from Israel, Pakistan, and Germany were also reported. In 2007, we described the late infantile variant phenotype caused by a missense mutation at the CLN8 gene (763C>G). This child with rapidly progressive disease within 3 years lost his mobility and manifested dementia, seizures, and profound visual loss. Subsequently we identified two additional children in the same pedigree with the same mutation and a considerably milder phenotype. Six and 3 years, respectively, after their onset of signs, they do not manifest motor disabilities, their cognitive regression and visual deficit are less appreciable, and only one manifests epilepsy. The reason for this clinical heterogeneity is unclear, although the presence of additional unknown mutated regulatory genes or epigenetic factors may explain it.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22964447     DOI: 10.1016/j.pediatrneurol.2012.05.016

Source DB:  PubMed          Journal:  Pediatr Neurol        ISSN: 0887-8994            Impact factor:   3.372


  7 in total

1.  The Neuronal Ceroid Lipofuscinoses-Linked Loss of Function CLN5 and CLN8 Variants Disrupt Normal Lysosomal Function.

Authors:  Shaho Parvin; Maryam Rezazadeh; Hassan Hosseinzadeh; Mohsen Moradi; Shadi Shiva; Jalal Gharesouran
Journal:  Neuromolecular Med       Date:  2019-03-27       Impact factor: 3.843

2.  Atypical presentation of neuronal ceroid lipofuscinosis type 8 in a sibling pair and review of the eye findings and neurological features.

Authors:  Rossana L Sanchez; Jiong Yan; Sarah Richards; Gary Mierau; Eric P Wartchow; Christin D Collins; Suma P Shankar
Journal:  Am J Ophthalmol Case Rep       Date:  2016-08-27

3.  Next-generation sequencing identifies unexpected genotype-phenotype correlations in patients with retinitis pigmentosa.

Authors:  Johannes Birtel; Martin Gliem; Elisabeth Mangold; Philipp L Müller; Frank G Holz; Christine Neuhaus; Steffen Lenzner; Diana Zahnleiter; Christian Betz; Tobias Eisenberger; Hanno J Bolz; Peter Charbel Issa
Journal:  PLoS One       Date:  2018-12-13       Impact factor: 3.240

4.  Retinal degeneration in mice and humans with neuronal ceroid lipofuscinosis type 8.

Authors:  Elyse M Salpeter; Brian C Leonard; Antonio J Lopez; Christopher J Murphy; Sara Thomasy; Denise M Imai; Kristin Grimsrud; K C Kent Lloyd; Jiong Yan; Rossana Sanchez Russo; Suma P Shankar; Ala Moshiri
Journal:  Ann Transl Med       Date:  2021-08

5.  CLN8 Gene Compound Heterozygous Variants: A New Case and Protein Bioinformatics Analyses.

Authors:  Rajech Sharkia; Abdelnaser Zalan; Hazar Zahalka; Amit Kessel; Ayman Asaly; Wasif Al-Shareef; Muhammad Mahajnah
Journal:  Genes (Basel)       Date:  2022-08-05       Impact factor: 4.141

6.  CLN8 Mutations Presenting with a Phenotypic Continuum of Neuronal Ceroid Lipofuscinosis-Literature Review and Case Report.

Authors:  Magdalena Badura-Stronka; Anna Winczewska-Wiktor; Anna Pietrzak; Adam Sebastian Hirschfeld; Tomasz Zemojtel; Katarzyna Wołyńska; Katarzyna Bednarek-Rajewska; Monika Seget-Dubaniewicz; Agnieszka Matheisel; Anna Latos-Bielenska; Barbara Steinborn
Journal:  Genes (Basel)       Date:  2021-06-23       Impact factor: 4.096

7.  Gene expression profiling of rubella virus infected primary endothelial cells of fetal and adult origin.

Authors:  Henriette Geyer; Michael Bauer; Jennifer Neumann; Amy Lüdde; Paul Rennert; Nicole Friedrich; Claudia Claus; Ludmilla Perelygina; Annette Mankertz
Journal:  Virol J       Date:  2016-02-02       Impact factor: 4.099

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.